Rezolute, Inc., trading on the OTC Markets under the symbol RZLTD, is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on the discovery and development of allosteric modulators for the treatment of rare metabolic and endocrine disorders. Leveraging its proprietary Native Protein Functional Modulators (NPFM) platform, Rezolute aims to fine-tune native protein function to restore physiological balance in patients with hormone resistance syndromes and enzyme deficiency diseases.
The company’s lead program, RZ358, is an investigational allosteric modulator of the insulin receptor for congenital hyperinsulinism (CHI), a rare genetic disorder characterized by excessive insulin secretion and persistent hypoglycemia. Rezolute is advancing RZ358 through clinical trials designed to assess safety, tolerability, pharmacokinetics, and efficacy in reducing hypoglycemic events. In parallel, Rezolute is developing RZ402, a small molecule activator of phenylalanine hydroxylase for phenylketonuria (PKU), supported by preclinical data demonstrating its ability to enhance enzyme function and lower toxic phenylalanine levels.
Under the leadership of President and CEO Siddarth Lehal, Rezolute collaborates with academic research centers, patient advocacy organizations, and clinical research networks to conduct trials across the United States and Europe. Although the company is yet to secure regulatory approval for its pipeline candidates, its precision-driven approach and focus on high unmet medical needs position Rezolute as a potential innovator in the specialty biopharmaceutical sector.
AI Generated. May Contain Errors.
